Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020115183 - NEW CRYSTALLINE FORMS OF A MCL-1 INHIBITOR, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Publication Number WO/2020/115183
Publication Date 11.06.2020
International Application No. PCT/EP2019/083773
International Filing Date 05.12.2019
IPC
C07D 495/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
495Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 37/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 37/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
C07D 495/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
495Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • LES LABORATOIRES SERVIER [FR]/[FR]
  • VERNALIS (R&D) LIMITED [GB]/[GB]
Inventors
  • DE BAETS, Emilie
  • AUVRAY, Julien
  • LYNCH, Michael
  • LEBLANC, Nicolas
Common Representative
  • LES LABORATOIRES SERVIER
Priority Data
18306634.906.12.2018EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NEW CRYSTALLINE FORMS OF A MCL-1 INHIBITOR, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
(FR) NOUVELLES FORMES CRISTALLINES D'UN INHIBITEUR MCL-1, PROCÉDÉ DE PRÉPARATION ASSOCIÉ ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
Abstract
(EN)
Crystalline forms of Compound A: (I) characterized by its X-ray powder diffraction diagram,solid-state 13C NMR spectrum, MIR spectrum and Raman spectrum and pharmaceutical compositions containing it.
(FR)
La présente invention concerne des formes cristallines du composé A : (I) caractérisées par leur diagramme de diffraction de rayons X sur poudre, le spectre 13C NMR à l'état solide, le spectre MIR et le spectre Raman ainsi que des compositions pharmaceutiques les contenant.
Latest bibliographic data on file with the International Bureau